October 22, 2014Open Access

Ensuring Patient Privacy in Data Sharing for Postapproval Research

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Postapproval studies of drugs and devices are essential to identify late adverse events, but patients' privacy must be protected when EMR data are shared. This article discusses ways to balance the need for high-quality postapproval information and respect for patients' privacy.

Leer artículo completoexternamente

Me gusta

Guardar

Ver artículo completo

Cite This Study

Sarpatwari et al. (Wed,) studied this question.

synapsesocial.com/papers/6a1d1a6d73c56dd1bd2f2d89 https://doi.org/https://doi.org/10.1056/nejmsb1405487

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Does HIPAA preemption pose a legal barrier to health information transparency and interoperability2007 · 3 citations
2Safety and effectiveness of adalimumab in patients with rheumatoid arthritis over 5 years of therapy in a phase 3b and subsequent postmarketing observational study2014 · 29 citations
3Using software agents to preserve individual health data confidentiality in micro-scale geographical analyses2005 · 55 citations
4Development of a Large-Scale De-Identified DNA Biobank to Enable Personalized Medicine2008 · 1,028 citations
5A prospective, claims‐based assessment of the risk of pancreatitis and pancreatic cancer with liraglutide compared to other antidiabetic drugs2013 · 81 citations

Me gusta

Guardar

Ver artículo completo